Navigation Links
Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis
Date:10/15/2007

, rater-blinded study that will compare alemtuzumab to Rebif(R) as first-line therapy for patients with relapsing-remitting multiple sclerosis (MS). The second Phase 3 study, CARE-MS II, also has begun and will enroll patients who have continued to experience relapse episodes while on currently available disease-modifying therapies.

Phase 2 Trial Design

The phase 2 trial randomized 334 patients with active relapsing-remitting multiple sclerosis at 49 medical centers in Europe and the United States. Patients in the trial were treated with alemtuzumab at one of two doses (12 or 24/mg per day intravenously for five days at initial treatment, and three days of re-treatment after 12 months with an option to treat again at 24 months), or interferon beta-1a (44 mcg administered by subcutaneous injection three times per week, as indicated in its product label).

The randomized trial compared the efficacy of alemtuzumab with interferon beta-1a using two primary endpoints: the rate of relapse of MS symptoms, and the time to Sustained Accumulation of Disability over six months as measured by Expanded Disability Status Scale [EDSS]. Efficacy assessments were made by independent neurologists blinded to therapy.

Alemtuzumab is an investigational drug for the treatment of MS and must not be used outside of a formal clinical trial setting in MS patients. Physicians or patients seeking additional information about the recently-initiated CARE-MS I Phase 3 trial should contact Genzyme Medical Information at 1-800-745-4447, option 2 in the United States, + 31 35 6991499 in Europe, or visit http://www.clinicaltrials.gov.

About Multiple Sclerosis

Multiple Sclerosis (MS) is a chronic, debilitating disease in which the immune system attacks the person's brain and spinal cord. The disease causes a wide range of symptoms including fatigue, difficulty walking, numbness, and vision problems, and can pr
'/>"/>

SOURCE Genzyme Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
2. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
3. Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line Results with ...
4. Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201
5. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
6. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys Investigational Drug to Treat Cocaine and Methamphetamine Addiction
7. Cobalis Expects to Report Phase III Top-Line Results in May
8. XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512 in Restless Legs Syndrome
9. Amarin Reports Top-Line Results of two Phase III Studies of Miraxion in Huntingtons Disease
10. UCB Announces Positive Top-Line Phase III Results for Keppra as Adjunctive Therapy for Partial Onset Seizures in Paediatric Patients from One Month to Less than Four Years of Age
11. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Kan. , July 24, 2014  Parnell ... two compounds that will be added to Parnell,s ... Australian-based CIMTECH Pty Ltd, a biotechnology company. The ... 122 have shown promise in bone regeneration and ... to develop the compounds for the veterinary market ...
(Date:7/24/2014)... 24, 2014  Uroplasty, Inc. (NASDAQ: UPI ... and markets innovative proprietary products to treat voiding ... 2015 first quarter ended June 30, 2014.  ... Neuromodulation System grew 19% to $4.1 million, as ... of the prior year.  Total revenue for the ...
(Date:7/24/2014)... 24, 2014 Omnicell, Inc. (NASDAQ: ... and supply management solutions and analytics software for ... 31, to discuss the Company,s Second Quarter 2014 ... 2014 earnings conference call and webcastWhen: , ... Lipps, chairman, president and chief executive officer ...
Breaking Medicine Technology:Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2
... Get employees moving to improve health with MapWalk ... www.hesonline.com ). The company makes this fun, easy tool free to wellness program ... , , ... , Using Google Maps ...
... June 3 Today, Roche honored 11 outstanding Ph.D. students ... for research accomplishments in the field of organic chemistry. The winners are ... Chemistry to gain first hand knowledge on the important role organic ... , , ...
Cached Medicine Technology:Exclusive Mapping Tool Helps Create Walking Communities 2Exclusive Mapping Tool Helps Create Walking Communities 3Roche Symposium Showcases Accomplishments of Next Generation of Chemists 2Roche Symposium Showcases Accomplishments of Next Generation of Chemists 3Roche Symposium Showcases Accomplishments of Next Generation of Chemists 4Roche Symposium Showcases Accomplishments of Next Generation of Chemists 5
(Date:7/25/2014)... Reproductive Science Center (RSC) of New ... Luzzo, Lead Physician at RSC Rhode Island, received the ... in fertility care and community outreach issued by Providence ... PBN Awards ceremony held July 24th at Salve Regina ... highly regarded, emerging leaders in their field were recognized ...
(Date:7/25/2014)... Florida Hospital and MOSI officially announced a transformational partnership that ... and make a difference in the Tampa Bay community. Florida ... provide the support needed to keep the science center moving ... IMAX Dome Theatre from film to a state-of-the-art digital 3D ... in the state of Florida, and it is one of ...
(Date:7/25/2014)... human brain can preserve oxygen to protect itself from ... Although dehydration significantly reduces blood flow to the ... compensates by increasing the amount of oxygen it extracts ... understand a lot more about how the human brain ... author Steven Trangmar, a researcher at Brunel University, said ...
(Date:7/25/2014)... July 25, 2014 AttorneyOne.com, a recognized authority ... information from the FDA on Ibuprofen and Oxcarbazepine Tablets ... one lot of Ibuprofen and one lot of Oxcarbazepine Tablets, ... to mislabeled packaging. Oxcarbazepine is used for the treatment of ... , The reason for the recall is that Lot #142588, ...
(Date:7/25/2014)... 2014 A new study conducted by the ... 39 percent of all children in the survey under the age ... looked at 2,505 children during the years of 2011 and 2013. ... age. The final result was that about two out of ... these children were from lower-income families and were of East Asian ...
Breaking Medicine News(10 mins):Health News:Dr. Kerri Luzzo of the Reproductive Science Center of Providence Receives “40 Under Forty Award" for Outstanding Professional Accomplishments and Community Outreach 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 3Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 4Health News:Human Brain Has Coping Mechanism for Dehydration 2Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 3
... Brooklyn, New York , has been included in the Strathmore,s Who,s Who Worldwide Edition for his outstanding contributions and achievements in the field of healthcare. , ... , , ... ... ABOUT DR. MARK RUSSELL , ...
... Stonebranch, the industry leader in Managed File Transfer ... , announced today the publication of its most recent white ... for U.S. Healthcare Organizations, Communications and Business Processes." The ... (HCOs), related covered entities (CE) and business associates (BA) can ...
... see the world almost five times faster than humans, according ... London. This gives bumblebees the fastest colour vision of ... find food, write Dr Peter Skorupski and Prof Lars Chittka ... to see at high speed is common in fast-flying insects; ...
... shows , WEDNESDAY, March 17 (HealthDay News) -- People ... work can recover an average of four months earlier if ... a new study suggests. , Researchers in the Netherlands and ... hadn,t been able to go to work for about six ...
... , ... Press Publisher Jed Morey penned an investigative piece this week on the Native American ... Tobacco” to push a bill through Congress that halts the practice of sending cigarettes ... ...
... ... WildCoins to purchase laptops for needy children throughout the world , ... Redmond, Wash. (PRWEB) March 17, 2010 ... collaborative effort between WildTangent and its more than 40 million customers worldwide to donate ...
Cached Medicine News:Health News:Dr. Mark Russell Recognized By Strathmore's Who's Who Worldwide Publication 2Health News:Stonebranch Publishes Healthcare IT White Paper 2Health News:Stonebranch Publishes Healthcare IT White Paper 3Health News:Stonebranch Publishes Healthcare IT White Paper 4Health News:Bees see super color at super speed 2Health News:WildTangent Launches “WildCoins for Kids” Program 2Health News:WildTangent Launches “WildCoins for Kids” Program 3
... Goldmann standard automatic or manual ... with white/white, blue/yellow or red/white stimuli/background ... or classic 4-2 threshold strategy. Examination ... grids (including 30-2, 24-2, and 10-2). ...
The Oculus easyfield is an exciting new compact perimeter to do automatic static perimetry up to 30 degrees eccentricity. It has been designed for the combined use as a visual field screener and peri...
... Designed around the patented Interzeag ... 301 sets the trend in ... Ideal for routine screening and ... performance, accuracy and quality of ...
Focus Toric Monthly lenses. All the advantages of Focus Monthly lenses, now available for patients with astigmatism. Recommended for daily wear. Also approved for extended wear (1-7 days)....
Medicine Products: